

Therapies for Resistant and Recurrent Metastatic Cancer

<https://marketpublishers.com/r/T2AD0EA4700EN.html>

Date: November 2017

Pages: 338

Price: US\$ 2,475.00 (Single User License)

ID: T2AD0EA4700EN

Abstracts

The global cancer therapeutics market should reach \$172.6 billion by 2022 from \$121 billion in 2017 at a compound annual growth rate (CAGR) of 7.4%, from 2017 to 2022.

The lung cancer market is expected to grow from \$15.7 billion in 2017 to \$22.6 billion in 2022 at a CAGR of 7.6% for the period 2017-2022.

The stomach cancer segment of the global cancer therapeutics market is expected to grow from \$8.2 billion in 2017 to \$11.9 billion in 2022 at a CAGR of 7.7% for the period 2017-2022.

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Scope of Report
Methodology and Information Sources
Primary Data and Information Gathering
Secondary Data and Information Gathering
Market Share Analysis and Market Forecast Prediction
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS

CHAPTER 3 INCIDENCE, PREVALENCE AND MORTALITY STATISTICS FOR CANCER: A GLOBAL SUMMARY

Cancer: The Disease
Cancer: A Statistical Analysis of the Disease Incidence and Prevalence
Regional Patterns of Cancer
The Global Cancer Burden and Worldwide Cancer Risk Factors
Incidence and Prevalence Rates for Major Cancer Types
Europe
North America
Asia-Pacific
Latin and Central America
Middle East/Africa
Tobacco Use and Statistics
Alcohol Abuse and Cancer Statistics
Obesity and Cancer Statistics
Infectious Diseases and Cancer
Inherited Genes/Diseases and Cancer
BRCA1 and BRCA2 Genes
TP53 and PTEN
Sun, Ultraviolet Radiation and Cancer
Hormones and Cancer

CHAPTER 4 METASTASIS AND CURRENT UNDERSTANDING OF THE MECHANISMS OF RESISTANCE AND RECURRENCE IN METASTATIC CANCER

What is Metastatic Cancer

Pathophysiology

Routes of Metastasis

Diagnosis

Classification of Metastasis

Metastasis: Common Sites of Origin

The Lung

The Breast

Melanoma

The Colon

The Kidney

The Prostate

Types of Prostate Cancer

Acinar Adenocarcinoma

Ductal Adenocarcinoma

Transitional Cell (or urothelial) Cancer

Squamous Cell Cancer

Small Cell Prostate Cancer

Other Rare Prostate Cancers

The Pancreas

Other rare types of pancreatic cancer

Pancreatoblastoma

Sarcomas of the Pancreas

Lymphoma

The Liver

Types of primary liver cancer

Hepatocellular Carcinoma (Hepatocellular Cancer) (HCC)

Intrahepatic Cholangiocarcinoma (Bile Duct Cancer)

Angiosarcoma and Hemangiosarcoma

Hepatoblastoma

Secondary Liver Cancer (Metastatic Liver Cancer)

The Cervix

Essential Understanding in Cancer Biology

Current Understanding of Mechanisms of Resistance and Recurrence in Metastatic Cancer

Inherent Resistance

Acquired Resistance
Altered Membrane Transport
Enhanced DNA Repair
Apoptotic Pathway Defects
Alteration of Target Molecules
Protein and Pathway Mechanisms
Genome Alterations (Gene Amplification and Deletion)
Epigenetic Modifications

CHAPTER 5 CANCER: CURRENT THERAPY STRATEGIES

General Treatment Strategies
Cancer Drug Treatment Strategies
Hormonal Cancer Drug Therapy
Targeted Biologic Therapy
Cytotoxic Cancer Drugs Therapies
Surgery for Cancer
Radiotherapy for Cancer
Cytotoxic Cancer Chemotherapy
Cytotoxic Cancer Drugs Classification
Alkylating and Alkylating-Like Agents
Antimetabolites
Antitumor Antibiotics
Plant alkaloids
Miscellaneous agents
Hormone-based Cancer Drugs
Targeted Biologic Therapy
Monoclonal Antibodies (MAB)
Types of Monoclonal Antibodies
Naked Monoclonal Antibodies
Conjugated Monoclonal Antibodies
Radiolabeled Antibodies
Chemolabeled Antibodies
Bispecific Monoclonal Antibodies
Drugs that Target PD-1 or PD-L1
PD-1 Inhibitors
PD-L1 inhibitors
Drugs that target CTLA-4
Cancer Growth Blockers

mTOR Inhibitors
Second Generation mTOR Inhibitors
Proteasome Inhibitors
Phosphoinositide 3-Kinase Inhibitors (PI3K Inhibitors)
Idelalisib (Zydelig) (Gilead Sciences)
Histone Deacetylase Inhibitors
Tyrosine Kinase Inhibitors (TKIs)
Hedgehog Pathway Blockers
Blood Cell Growth Factors
Cancer Vaccines
Gene Therapy
Drugs that Block Cancer Blood Vessel Growth (Antiangiogenics)
Cytokines (Interferon and Interleukin 2)
Personalized Cancer Therapy (Precision Medicine)

CHAPTER 6 METASTATIC CANCER TREATMENT OPTIONS BY TUMOR ORIGIN

Bladder
Surgery
Radiation Therapy
Chemotherapy
Immunotherapy
Avelumab (Bavencio)
Nivolumab (Opdivo)
Pembrolizumab (Keytruda)
Durvalumab (Imfinzi)
Atezolizumab (Tecentriq)
Breast
Hormone Therapy
Blocking Estrogen's Effects
Selective Estrogen Receptor Modulators (SERMs)
Other Antiestrogen Drugs
Blocking Estrogen Production
Blocking Ovarian Function
Targeted Therapy
Chemotherapy and Radiology
Chemotherapy
Anthracyclines
Alkylating Agents

Taxanes
Other Microtubule Inhibitors
Antimetabolites
Platinum-based Chemotherapy
Chemotherapy Combinations
Radiation Therapy
Other Treatment Options
Surgery
Colorectal
Standard Treatment Options for Stage IV and Recurrent Rectal Cancer
Surgery with or without Chemotherapy or Radiation Therapy
First-line Chemotherapy and Targeted Therapy
Fluorouracil (5-FU)
Irinotecan
Oxaliplatin (Eloxatin)
Capecitabine
FOLFOXIRI (Irinotecan, Oxaliplatin, Leucovorin [LV], and 5-FU)
Bevacizumab
Cetuximab
Aflibercept
Ramucirumab
Panitumumab
Anti-EGFR Antibodies
Regorafenib
TAS-102
Second-line Chemotherapy
Palliative Therapy
Treatment of Liver Metastasis
Standard Treatment Options for Stage IV and Recurrent Colon Cancer
Kidney
Renal Cell Cancer (RCC) Treatment
Surgery
Radiation Therapy
Chemotherapy
Immunotherapy or Biologic Therapy
Targeted Therapy
Anti-angiogenesis Therapy
Tyrosine Kinase Inhibitors (TKIs)
mTOR Inhibitors

Transitional Cell Cancer (TCC) of the Renal Pelvis and Ureter

Lung

Treatment Options for Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)

Surgery

Radiation therapy

Chemotherapy

Types of Chemotherapy

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Targeted Therapy

Monoclonal Antibodies

Tyrosine Kinase Inhibitors

Treatments for Metastatic Lung Cancer to the Liver

Research Options and Objectives

Melanoma

Treatments for Stage IV Melanoma, Recurrent and Metastatic Melanoma

Immunotherapy

Immune Checkpoint Inhibitor Therapy

Targeted Therapy

Signal Transduction Inhibitor Therapy

Oncolytic Virus Therapy

Angiogenesis Inhibitors

Ovary

Treatments for Stage IV Melanoma, Recurrent and Metastatic Melanoma

Pancreas

Prostate

Radiation Therapy

Hormone Therapy

Androgen Deprivation, an Adjuvant Therapy

Immunotherapy/Therapeutic Vaccines

Vascular-Targeted Photodynamic Therapy

Stomach

Surgery

Chemotherapy

Radiation Therapy

Chemoradiation Therapy

Targeted Therapy

Thyroid

Surgery
Radiation Therapy, Including Radioactive Iodine Therapy
External Beam Radiation Therapy for Thyroid Cancer
Targeted Therapy
Uterus

CHAPTER 7 GLOBAL MARKET FOR CANCER THERAPEUTICS BY CANCER TYPE

Global Cancer Therapeutics Market, by Cancer Type

Market Dynamics

Global Market Drivers

Increasing Cancer Prevalence Rates and Aging Population

Rising Awareness among People with Cancer and its Treatment

Continued Emphasis on R&D activities in Cancer and Treatment Technologies

Promised Potential of Alternative Therapies, e.g., Gene Therapy and Personalized Medicine

Greater Understanding of the Genetic Base of Individual Cancers

Fast Track Designation of Approvals and Clinical Trials

Introduction of a Range of Initiatives to Support New and Innovative Therapeutics for Cancer

The Cancer Moonshot

The Genomic Data Commons

The National Clinical Trials Network (NCTN)

The RAS Initiative

Collaborations, Partnerships, and Acquisitions having Major Impact on Industry

Strategic Approach

Global Market Restraints

Requirement to Provide Sufficient Data and Proof of Efficacy to obtain Reimbursement for New and Innovative Technologies

Unpredictability and Uncertainty of Clinical Trials

High Capital Investment and Low Benefit-Cost Ratio Risks Associated with Healthcare Technology Related Development Programs

Patents Expiration of Leading Drugs, Commercialization of Biosimilars and Decline in ASPs

Highly Competitive Market Crowded with Proprietary Technologies

Regional Cancer Drugs Market Assessment: North America

Selected Market Drivers: North America

The Increasing Burden of Cancer in the United States

Standardized Combination Chemotherapy Contributing to Increased Survival and Cure

Rates

Increased Survival Rates for Metastatic Breast Cancer (MBC) in the United States

Patient Assistance Programs (PAPs)

Increased Rates of Metastatic Prostate Cancer Cases in the United States

Selected Market Restraints: North America

Restricted and Increased Control of Access to Cancer Care After ACA

Increased Cost Sharing

The Current Product Approval System Stifles Innovation

Selected Country: Cancer Drugs Market, by Cancer Type

United States

Canada

Regional Cancer Drugs Market Assessment: Europe

Selected Market Drivers: Europe

Growing Aging Population in Europe

Latest Technological Advances and Innovations Helping to Develop Cancer Therapy

Market in Europe

Development of Combination Chemotherapy

Advances in Hormonal Therapy

Antiangiogenesis Agents

Emergence of Personalized Medicine

Acquisitions and Collaborations - Bolt-On Strategies Driving the Market Growth

Selected Market Restraints: Europe

Austerity Measures have been Introduced Throughout Europe

Increased Competitive Product Pricing and Mandatory Tendering Regarded as a Major Market Restraint

Revolutionary Cancer Treatments in Europe

Continued Market Appearance of Generics and Biosimilars

Selected Country: Cancer Drugs Market, by Cancer Type

France

Germany

Other European Countries

Regional Cancer Drugs Market Assessment: Asia-Pacific

Selected Market Drivers: Asia-Pacific

Aging Demographics in Japan

Growth in the Indian Market

The Impact of the Chinese Government's 2012 Healthcare Reform Plan on the Diagnostics Market

China: Cancer Rates Growing "Ferociously"

Selected Market Restraints: Asia-Pacific

Specific Market Restraints Relating to China
Specific Market Restraints Relating to India
Specific Market Restraints Relating to Japan
Selected Country: Cancer Drugs Market, by Cancer Type
Regional Cancer Drugs Market Assessment: Central and Latin America
Selected Market Drivers: Central and Latin America
Significant Market Growth Opportunities in Brazil
Growth in Private Healthcare and Private Insurance Plans
Expansion and Modernization of Top Private Hospitals
Government Support to Boost Brazil Healthcare Sector
Expansion of Pharmaceutical Healthcare Opportunities in Mexico
Introduction of Tax-funded Universal Health Coverage Throughout Latin America
Selected Market Restraints: Central and Latin America
Diverse Regulatory Environment Constraints Latin American Pharmaceutical Market
Challenges Associated with Local Business Practices and Cultural Conditions in Brazil
Limited Reimbursement System in Brazil
Pricing Issues
Selected Country: Cancer Drugs Market, by Cancer Type
Regional Cancer Drugs Market Assessment: Middle East/Africa
Selected Market Drivers: Middle East/Africa
Substantial Financial Support for Healthcare in Saudi Arabia
South Africa's Political Stability and Improved Economic Outlook Helps Support Growth in the Healthcare Market
Selected Market Restraints: Middle East/Africa
Limited Infrastructure Capacity Throughout Africa
Inherent Political and Economic Issues Constrain the Provision of Healthcare in Africa
Poor Distribution Structure and Networks in Africa
Medical Tourism to India for African Patients Requiring High-Frequency Ultrasound for Prostate Cancer
Selected Region: Cancer Drugs Market, by Cancer Type

CHAPTER 8 REGULATORY AND LEGISLATIVE REQUIREMENTS

The United States
Canada
Europe
Mutual Recognition Procedure (MRP)
Decentralized Procedure (DCP)
Centralized Procedure (CP)

Japan

China

India

South Korea

Brazil

Argentina

Mexico

South Africa

Saudi Arabia

Marketing Authorization System

Pharmaceutical Reimbursement Approval Process in Japan

Overview of the Healthcare System

Pharmaceutical Regulatory and Legislative Developments: China

Overview of the Healthcare System

National Level

State Level

Regional Level

District Level

Sub-Divisional/Taluka Level

Community Level

Primary Health Center's (PHC) Level

Sub Health Center (SHC) Level

Hospital Resources

Population Statistics

Pharmaceutical Regulatory and Legislative Developments: India

Regulatory and Legislative Requirements

Pharmaceutical Regulatory and Legislative Developments: South Korea

Pharmaceutical Reimbursement: South Korea

Market Entry and Reimbursement of Pharmaceuticals

Background

Government-funded Public Health Sector

Social Health Insurance Sector

Private Sector

Regulatory and Legislative Requirements

Regulation and Regulation Governing Medical Devices and Drugs in Mexico

Health Insurance Structure in Mexico

Instituto Mexicano del Seguro Social (IMSS)

Seguro Popular (SP) or "People's Insurance"

Regulatory Requirements: South Africa

Health Insurance Structure: South Africa
Reimbursement of Pharmaceuticals: South Africa
The Public Healthcare System
Primary Healthcare Services
Secondary and Tertiary Healthcare Services
The Private Healthcare Sector
Pharmaceutical Regulatory Requirements: Saudi Arabia

CHAPTER 9 PATENT REVIEW/ NEW DEVELOPMENTS

Filed Patents by Clinical Application
Filed Patents and Expiry Dates for Major Products by Leading Suppliers
Filed Patents and Expiry Dates for Other Products and Suppliers
Filed Patents Cited for Metastatic Breast Cancer (01-01-2016 to 05-26-2017)
Filed Patents Cited for Metastatic Lung Cancer (11-05-2015 to 05-11-2017)
Filed Patents Cited for Other Cancer Types (11-05-2015 to 06-07-2017)
Pfizer Inc.
Merck & Co.
Johnson & Johnson
F Hoffman La Roche
Sanofi S.A.
Novartis AG
Gleevec/Glivec
Tasigna
Sandostatin
Sandostatin LAR
Afinitor/Votubia and Afinitor Disperz/Votubia Dispersible Tablets
Exjade
Jadenu
Votrient (Pazopanib)
Tafinlar (Dabrafenib)
Mekinist (Trametinib)
Promacta/Revolade
Zykadia (LDK378, ceritinib)
Farydak
Abbvie Inc.
Imbruvica (Ibrutinib)
Venclexta (venetoclax)
AstraZeneca PLC

Iressa (Gefitinib)
Faslodex (Fulvestrant)
Lynparza
Tagrisso (Osimertinib)
Zoladex
Caprelsa (Vandetanib)
Gilead Sciences
Targeting Breakpoint Cluster Region-Abelson (BCR-ABL)
Targeting Epidermal Growth Factor Receptor (EGFR/ERBB1)
Targeting Vascular Endothelial Growth Factor Receptor (VEGFR), PDGFR and Ret
Proto-Oncogene (RET)
Latest Approved Immunotherapy Drugs
Ponatinib (Iclusig) Incyte Corporation
Sprycel (Dasatinib) (Bristol-Myers Squibb)
Giotrif (Afatinib) (Boehringer Ingelheim)
Tyverb (Lapatinib) (Novartis)
Cometriq (Cabozantinib) (Exelixis, Inc)
Vargatef/Ofev (Nintedanib) (Boehringer-Ingelheim)
Stivarga (Regorafenib) (Bayer Healthcare)
Nexavar (Sorafenib) (Bayer Healthcare)

CHAPTER 10 COMPANY PROFILES

The Top 10 Multinational Pharmaceutical Companies

ABBVIE INC.

AMGEN

ASTRAZENECA PLC

GILEAD SCIENCES

F HOFFMAN LA ROCHE AG

JOHNSON & JOHNSON

MERCK & CO., INC.

NOVARTIS AG

PFIZER, INC.

SANOFI S.A.

Other Key Pharmaceutical Company Suppliers

ARRAY BIOPHARMA INC.

ASTELLAS PHARMA INC.

BAYER HEALTHCARE

BIOGEN, INC.

BRISTOL-MYERS SQUIBB
CASCADIAN THERAPEUTICS INC.
CELGENE CORPORATION
CELLDEX THERAPEUTICS, INC.
EISAI CO., LTD.
ELI LILLY AND COMPANY
GALENA BIOPHARMA, INC.
GLAXOSMITHKLINE
IMMUNOCELLULAR THERAPEUTICS, LTD.
IMMUNOGEN, INC.
INCYTE CORPORATION
INFINITY PHARMACEUTICALS, INC.
NEW LINK GENETICS CORP.
OTSUKA HOLDINGS CO., LTD.
TAKEDA PHARMACEUTICALS
REGENERON PHARMACEUTICALS, INC.
VERASTEM INC.

CHAPTER 11 COMPANY CONTACT DETAILS

Company Addresses and Contact Details
Government Regulatory Agencies and Professional Organizations
Commonly Used Acronyms Associated with Metastatic and Recurrent Cancer
Stage I and Stage II Endometrial Cancer
Chemotherapy
Hormone Therapy
Biologic Therapy
Further Research and Clinical Trials
Low-risk Endometrial Cancer (Grade 1 or Grade 2)
High-risk Endometrial Cancer (Grade 3)
Stage III, Stage IV, and Recurrent Endometrial Cancer
Rapamycin (mTOR) inhibitors
Bevacizumab
Health Insurance Structure: Saudi Arabia

List Of Tables

LIST OF TABLES

Summary Table: Global Cancer Therapeutics Market, by Cancer Type, Through 2022

Table 1: Global Statistics: Estimated Incidence, Mortality and Five-Year Prevalence, 2012

Table 2: Global Statistics: Estimated Incidence, Mortality and Five-Year Prevalence (in Men and Women Combined), by Cancer Type, 2012

Table 3: Global Statistics: Estimated Incidence, Mortality and Five-Year Prevalence (Men), by Cancer Type, 2012

Table 4: Global Statistics: Estimated Incidence, Mortality and Five-Year Prevalence (Women), by Cancer Type, 2012

Table 5: Estimated Number of New Cancer Cases, by Sex: The United States, 2017

Table 6: Estimated Number of Deaths from Cancer, by Sex: The United States, 2017

Table 7: Common Sites for Metastasis

Table 8: Cancer Treatment Options

Table 9: Cancer Drug Treatment Classification

Table 10: Advantages of Minimally Invasive Surgery

Table 11: FDA Approved Therapeutic Monoclonal Antibodies used to Treat Cancer, 1997-2017

Table 12: Approved Tyrosine kinase inhibitors (TKIs) used to Treat Cancer

Table 13: Common Sites for Metastasis

Table 14: Common Chemotherapeutic Agents for Recurrent and Metastatic Breast Cancer

Table 15: Chemotherapeutic Combinations for Recurrent and Metastatic Breast Cancer

Table 16: Treatment Options for Stage IV and Recurrent Colon Cancer

Table 17: Drugs Approved for the Treatment of Lung Cancer

Table 18: Drugs Approved for the Treatment of Melanoma

Table 19: Drugs Approved for Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Table 20: Combination Drugs Approved for Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Table 21: Drugs Approved for Pancreatic Cancer

Table 22: Drugs Approved for Pancreatic Cancer

Table 23: Hormone Therapy for Prostate Cancer

Table 24: Drugs Approved for Prostate Cancer

Table 25: Drugs Approved for Stomach (Gastric) Cancer

Table 26: Drugs Combinations Approved for Stomach (Gastric) Cancer

Table 27: Drugs Approved for Gastroenteropancreatic Neuroendocrine Tumors

Table 28: Treatment Option Overview for Thyroid Cancer
Table 29: Drugs Approved for Thyroid Cancer
Table 30: Treatment Option Overview for Endometrial Cancer
Table 31: Global Cancer Therapeutics Market, Through 2022
Table 32: Global Cancer Therapeutics Market, by Cancer Type, Through 2022
Table 33: Global Cancer Therapeutics Market and Market Share, by Cancer Type, 2017
Table 34: North American Cancer Therapeutics Market, Through 2022
Table 35: North American Therapeutics Market, by Cancer Type, Through 2022
Table 36: North American Market Share, by Individual Country, 2017
Table 37: United States' Therapeutics Market, by Cancer Type, Through 2022
Table 38: Canadian Therapeutics Market, by Cancer Type, Through 2022
Table 39: European Cancer Therapeutics Market, Through 2022
Table 40: European Therapeutics Market, by Cancer Type, Through 2022
Table 41: European Market Share, by Individual Country, 2017
Table 42: France's Therapeutics Market, by Cancer Type, Through 2022
Table 43: Germany's Therapeutics Market, by Cancer Type, Through 2022
Table 44: Italy's Therapeutics Market, by Cancer Type, Through 2022
Table 45: Spain's Therapeutics Market, by Cancer Type, Through 2022
Table 46: United Kingdom's Therapeutics Market, by Cancer Type, Through 2022
Table 47: Benelux's Therapeutics Market, by Cancer Type, Through 2022
Table 48: Scandinavia's Therapeutics Market, by Cancer Type, Through 2022
Table 49: Rest of Europe's Therapeutics Market, by Cancer Type, Through 2022
Table 50: Asia-Pacific Cancer Therapeutics Market, Through 2022
Table 51: Asia-Pacific Therapeutics Market, by Cancer Type, Through 2022
Table 52: Asia-Pacific Market Share, by Individual Country, 2017
Table 53: Japanese Therapeutics Market, by Cancer Type, Through 2022
Table 54: Chinese Therapeutics Market, by Cancer Type, Through 2022
Table 55: Indian Therapeutics Market, by Cancer Type, Through 2022
Table 56: South Korean Therapeutics Market, by Cancer Type, Through 2022
Table 57: Taiwan's Therapeutics Market, by Cancer Type, Through 2022
Table 58: Rest of Asia-Pacific Therapeutics Market, by Cancer Type, Through 2022
Table 59: Central and Latin American Cancer Therapeutics Market, Through 2022
Table 60: Central and Latin American Therapeutics Market, by Cancer Type, Through 2022
Table 61: Central and Latin American Market Share, by Individual Country, 2017
Table 62: Argentina's Therapeutics Market, by Cancer Type, Through 2022
Table 63: Brazil's Therapeutics Market, by Cancer Type, Through 2022
Table 64: Chile's Therapeutics Market, by Cancer Type, Through 2022
Table 65: Mexico's Therapeutics Market, by Cancer Type, Through 2022

Table 66: Rest of Central and Latin America's Therapeutics Market, by Cancer Type, Through 2022

Table 67: Middle East/Africa's Cancer Therapeutics Market, Through 2022

Table 68: Middle East/Africa's Therapeutics Market, by Cancer Type, Through 2022

Table 69: Middle East/Africa's Market Share, by Individual Country, 2017

Table 70: Middle East's Therapeutics Market, by Cancer Type, Through 2022

Table 71: African Therapeutics Market, by Cancer Type, Through 2022

Table 72: Overview of Healthcare in India

Table 73: Latest Patent Publications Cited Relating to Metastatic Breast Cancer, 2016-May 2017

Table 74: Latest Patent Publications Cited Relating to Metastatic Prostate Cancer, 2015-May 2017

Table 75: Latest Patent Publications Cited Relating to Metastatic Lung Cancer, 2015-March 2017

Table 76: Latest Patent Publications Cited Relating to Other Metastatic Cancers, 2015-March 2017

Table 77: Pfizer Inc. Patent Expiry Dates for Leading Cancer Drugs

Table 78: Merck & Co Patent Status Leading Oncology Products

Table 79: Johnson & Johnson Patent Status Leading Oncology Products

Table 80: F Hoffman La Roche Patent Status Leading Oncology Products

Table 81: Sanofi S.A. Patent Status Leading Oncology Products

Table 82: AstraZeneca plc Patent Status Leading Oncology Products

Table 83: Top 10 Pharmaceutical Companies 2017

Table 84: Abbvie Inc. Company Financials, by Product, 2014-2016

Table 85: Amgen Company Financials, 2014-2016

Table 86: Amgen Company Financials, by Product, 2014-2016

Table 87: AstraZeneca plc Company Financials, by Therapeutic Product Group, 2014-2016

Table 88: AstraZeneca plc Company Financials, by Oncology Product Group, 2014-2016

Table 89: Gilead Sciences Summary Financials, 2014-2016

Table 90: Gilead Sciences Product Pipeline

Table 91: F Hoffman La Roche Summary Financials, 2014-2016

Table 92: F Hoffman La Roche Pharmaceutical Division Financials, 2014-2016

Table 93: F Hoffman La Roche Pharmaceutical Division Oncology Product Sales, 2014-2016

Table 94: Johnson & Johnson Summary Financials, 2014-2016

Table 95: Johnson & Johnson Pharmaceutical Therapeutic Area Product Sales, 2014-2016

Table 96: Johnson & Johnson Oncology Product Sales, 2014-2016
Table 97: Merck & Co Inc. Therapeutic Area Product Sales, 2014-2016
Table 98: Merck & Co Oncology Product Sales, 2014-2016
Table 99: Novartis AG Summary Financials, 2014-2016
Table 100: Novartis AG Summary Financials, 2014-2016
Table 101: Novartis AG Major Development Projects
Table 102: Pfizer, Inc. Summary Financials, 2014-2016
Table 103: Pfizer, Inc. Innovative Health (IH) Division Financials, 2014-2016
Table 104: Pfizer, Inc. Innovative Health (IH) Division Oncology Product Sales, 2014-2016
Table 105: Sanofi S.A. Summary Financials, 2014-2016
Table 106: Sanofi S.A. Oncology Product Sales, 2014-2016
Table 107: Array Biopharma Inc. Clinical Stage Drug Portfolio
Table 108: Astellas Pharma Inc Innovative Health (IH) Division Oncology Product Sales, 2014-2016
Table 109: Bayer AG Company Financials, 2014-2016
Table 110: Bayer AG Oncology Product Sales, 2014-2016
Table 111: Biogen, Inc. Summary Company Financials, 2014-2016
Table 112: Bristol-Myers Squibb Segment Product Sales, 2014-2016
Table 113: Bristol-Myers Squibb Oncology Product Sales, 2014-2016
Table 114: Celgene Corporation Financial Summary, 2014-2016
Table 115: Eisai Co., Ltd. Financial Summary, 2014-2016
Table 116: Eisai Co., Ltd Oncology Product Sales, 2014-2016
Table 117: Eli Lilly and Company Selected Product Sales, 2014-2016
Table 118: GlaxoSmithKline Financial Summary by Segment, 2014-2016
Table 119: GlaxoSmithKline Pharmaceuticals Turnover by Therapeutic Area, 2014-2016
Table 120: GlaxoSmithKline Oncology Product Pipeline
Table 121: Incyte Corporation Company Revenues, 2014-2016
Table 122: Tekada Company Revenues, 2014-2016
Table 123: Regeneron Pharmaceuticals, Inc. Company Revenues, 2014-2016
Table 124: Company Addresses and Contact Details
Table 125: Government Regulatory Agencies and Professional Organizations associated with Metastatic and Recurrent Cancer
Table 126: Commonly Used Acronyms Associated with Metastatic and Recurrent Cancer

List Of Figures

LIST OF FIGURES

Summary Figure: Global Cancer Therapeutics Market Share, by Cancer Type, 2017

Figure 1: Estimated World Cancer Incidence Proportions, by Cancer Type, in Men and Women Combined, 2012

Figure 2: Estimated World Cancer Incidence Proportions, by Cancer Type, in Men, 2012

Figure 3: Estimated World Cancer Incidence Proportions, by Cancer Type, in Women, 2012

Figure 4: Metastatic Sites for Common Cancers

Figure 5: Schematic of Acquired Resistance Mechanisms

Figure 6: The Intrinsic and Extrinsic Pathways of Apoptosis

Figure 7: Managing Locally Advanced or Metastatic Bladder Cancer

Figure 8: Global Market Share, by Cancer Type, 2017

Figure 9: All Cancers, Average Number of New Cases per Year and Age-Specific Incidence Rates, U.K. 2012-2014

Figure 10: North American Market Share, by Individual Country, 2017

Figure 11: Estimates and Projections of Metastatic Breast Cancer (MBC) Prevalence in the United States, 1990-2020

Figure 12: European Market Share, by Individual Country, 2017

Figure 13: Asia-Pacific's Market Share, by Individual Country, 2017

Figure 14: Central and Latin American Market Share, by Individual Country, 2017

Figure 15: Middle East/Africa's Market Share, by Individual Country, 2017

Figure 16: Drug Discovery and Development Time Line

Figure 17: Mutual Recognition Procedure

Figure 18: Decentralized Procedure

Figure 19: Japanese Drug Funding/Reimbursement Approval Procedure

Figure 20: The Chinese Healthcare System

Figure 21: Argentina: Regulatory Drug Approval Procedure Standard Review 120-240 Business Days for Approval

Figure 22: Current Structure of the Health Care Sectors in Saudi Arabia

COMPANIES MENTIONED

ABBVIE INC.

ARRAY BIOPHARMA INC.

ASTELLAS PHARMA INC.

ASTRAZENECA PLC

BAYER HEALTHCARE
BIOGEN, INC.
BRISTOL-MYERS SQUIBB
CASCADIAN THERAPEUTICS INC.
CELGENE CORPORATION
CELLDEX THERAPEUTICS, INC.
EISAI CO., LTD.
ELI LILLY AND COMPANY
F HOFFMAN LA ROCHE AG
GALENA BIOPHARMA, INC.
GILEAD SCIENCES
GLAXOSMITHKLINE
IMMUNOCELLULAR THERAPEUTICS, LTD.
IMMUNOGEN, INC.
INCYTE CORPORATION
INFINITY PHARMACEUTICALS, INC.
JOHNSON & JOHNSON
MERCK & CO., INC.
NEW LINK GENETICS CORP.
NOVARTIS AG
OTSUKA HOLDINGS CO., LTD.
PFIZER, INC.
REGENERON PHARMACEUTICALS, INC.
SANOFI S.A.
TAKEDA PHARMACEUTICALS
VERASTEM INC.

I would like to order

Product name: Therapies for Resistant and Recurrent Metastatic Cancer

Product link: <https://marketpublishers.com/r/T2AD0EA4700EN.html>

Price: US\$ 2,475.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T2AD0EA4700EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970